Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for 80-85% of all lung cancer cases. Find out more about testing and treatment here.
Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for 80-85% of all lung cancer cases. Find out more about testing and treatment here.
At Boehringer Ingelheim, addressing patient needs and fighting stigma in lung cancer care are two focus topics of the patient engagement team in oncology.
Combination therapy with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy.
For the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have activating epidermal growth factor receptor (EGFR) mutations. For the treatment of patients with locally advanced or metastatic NSCLC of squamous hist
Our goal of transforming the treatment of neuroendocrine carcinomas
Our progress in developing a potential DLL3 targeted immunotherapy for neuroendocrine carcinomas (NECs), including small cell lung cancer (SCLC), large cell NEC of the lung (LCNEC-L) and extrapulmonary NEC (epNEC).